KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Assets (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Assets for 8 consecutive years, with $578.6 million as the latest value for Q4 2025.

  • Quarterly Assets rose 8.91% to $578.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $578.6 million through Dec 2025, up 8.91% year-over-year, with the annual reading at $578.6 million for FY2025, 8.91% up from the prior year.
  • Assets hit $578.6 million in Q4 2025 for Castle Biosciences, up from $562.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $578.6 million in Q4 2025 to a low of $425.4 million in Q2 2023.
  • Historically, Assets has averaged $474.9 million across 5 years, with a median of $458.1 million in 2022.
  • Biggest five-year swings in Assets: soared 263.66% in 2021 and later fell 7.19% in 2023.
  • Year by year, Assets stood at $462.6 million in 2021, then dropped by 3.3% to $447.3 million in 2022, then rose by 1.34% to $453.3 million in 2023, then increased by 17.18% to $531.2 million in 2024, then increased by 8.91% to $578.6 million in 2025.
  • Business Quant data shows Assets for CSTL at $578.6 million in Q4 2025, $562.8 million in Q3 2025, and $544.7 million in Q2 2025.